A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00609674
First received: January 24, 2008
Last updated: January 5, 2010
Last verified: January 2010
  Purpose

The purpose of this study is to compare the effects (effectiveness and safety) of an intranasal corticosteroid (fluticasone furoate nasal spray [FFNS]), with a placebo nasal spray for the treatment of perennial (year-round) allergic rhinitis.


Condition Intervention Phase
Perennial Allergic Rhinitis
Drug: Fluticasone furoate nasal spray
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg in Adult and Adolescent Subjects 12 Years of Age and Older With Perennial Allergic Rhinitis (PAR)

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Mean Change From Baseline Over the Entire Treatment Period in Daily Reflective Total Nasal Symptom Scores (rTNSS) [ Time Frame: Daily; Baseline through End of Study (Week 4) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Mean Change From Baseline Over the Entire Treatment Period in Morning (AM), Pre-dose Instantaneous Total Nasal Symptom Score (iTNSS) [ Time Frame: Daily; Baseline through End of Study (Week 4) ] [ Designated as safety issue: No ]
  • Mean Change From Baseline Over the Entire Treatment Period in Daily Reflective Total Ocular Symptom Scores (rTOSS) [ Time Frame: Daily; Baseline through End of Study (Week 4) ] [ Designated as safety issue: No ]
  • Total Nasal Symptoms: Mean Change From Baseline Over the Entire Treatment Period in AM rTNSS [ Time Frame: Daily; Baseline through End of Study (Week 4) ] [ Designated as safety issue: No ]
  • Total Nasal Symptoms: Mean Change From Baseline Over the Entire Treatment Period in PM rTNSS [ Time Frame: Daily; Baseline through End of Study (Week 4) ] [ Designated as safety issue: No ]
  • Total Nasal Symptoms: Mean Percent Change From Baseline Over the Entire Treatment Period in Daily rTNSS and AM, Pre-dose iTNSS [ Time Frame: Daily; Baseline through End of Study (Week 4) ] [ Designated as safety issue: No ]
  • Individual Nasal Symptoms: Mean Change From Baseline Over the Entire Treatment Period in Individual Daily Reflective Nasal Symptom Scores and AM, Pre-dose Instantaneous Nasal Symptom Scores for Rhinorrhea, Nasal Congestion, Nasal Itching, and Sneezing [ Time Frame: Daily; Baseline through End of Study (Week 4) ] [ Designated as safety issue: No ]
  • Mean Change From Baseline Over the Entire Treatment Period in Both Individual AM Reflective and PM Reflective Nasal Symptom Scores for Rhinorrhea, Nasal Congestion, Nasal Itching, and Sneezing. [ Time Frame: Daily; Baseline through End of Study (Week 4) ] [ Designated as safety issue: No ]
  • Total Ocular Symptoms: Mean Change From Baseline Over the Entire Treatment Period in AM, Pre-dose Instantaneous Total Ocular Symptom Scores (iTOSS) [ Time Frame: Daily; Baseline through End of Study (Week 4) ] [ Designated as safety issue: No ]
  • Total Ocular Symptoms: Mean Change From Baseline Over the Entire Treatment Period in Both the AM Reflective Total Ocular Symptom Scores (rTOSS) and PM rTOSS [ Time Frame: Daily; Baseline through End of Study (Week 4) ] [ Designated as safety issue: No ]
  • Total Ocular Symptoms: Mean Percent Change From Baseline Over the Entire Treatment Period in Both the Daily rTOSS and the AM, Pre-dose iTOSS [ Time Frame: Daily; Baseline through End of Study (Week 4) ] [ Designated as safety issue: No ]
  • Individual Ocular Symptoms: Mean Change From Baseline Over the Entire Treatment Period in Both the Individual, Daily Reflective and the AM, Pre-dose Instantaneous Ocular Symptom Scores for Eyes Itching/Burning, Eyes Tearing/Watering, and Eye Redness. [ Time Frame: Daily; Baseline through End of Study (Week 4) ] [ Designated as safety issue: No ]
  • Mean Change From Baseline Over the Entire Treatment Period in Both the Individual AM Reflective and PM Reflective Ocular Symptom Scores for Eyes Itching/Burning, Eyes Tearing/Watering, and Eye Redness [ Time Frame: Daily; Baseline through End of Study (Week 4) ] [ Designated as safety issue: No ]
  • Peak Nasal Inspiratory Flow (PNIF): Mean Change From Baseline in Daily, AM, and PM PNIF [ Time Frame: Daily; Baseline through End of Study (Week 4) ] [ Designated as safety issue: No ]
  • Mean Change From Baseline to Endpoint in the Rhinoconjunctivitis Quality of Life Questionnaire With Standardised Activities (RQLQ[S]) [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]

Enrollment: 315
Study Start Date: January 2008
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
Placebo
Experimental: fluticasone furoate nasal spray Drug: Fluticasone furoate nasal spray
Fluticasone furoate nasal spray
Other Name: Fluticasone furoate nasal spray

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subjects eligible for enrollment in the study must meet all of the following criteria:

  • Informed consent
  • Subject has provided an appropriately signed and dated informed consent.
  • An appropriately signed and dated assent must be obtained from the parents or guardian if the subject is a child under 18 years of age.
  • Outpatient
  • Subject is treatable on an outpatient basis.
  • Age
  • ≥ 12 years at Visit 2
  • ≥ 18 years at Visit 1 for Russia and Germany
  • Male or eligible female. Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test will be performed for all females of childbearing potential at Visits 1, 2, 5, and Visit 6/Early Withdrawal to determine if the subject is pregnant.

To be eligible for entry into the study, females of childbearing potential must commit to the consistent and correct use of an acceptable method of birth control, as defined by the following:

  • Abstinence Females of childbearing potential who are not sexually active must commit to complete abstinence from intercourse for two weeks before exposure to the study drug, throughout the clinical trial, and for a period after the trial to account for elimination of the drug (minimum of six days).
  • Oral contraceptive (either combined estrogen/progestin or progestin only),
  • Injectable progestogen,
  • Implants of levonorgestrel,
  • Percutaneous contraceptive patches,
  • Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year,
  • Male partner who is sterile (vasectomy with documentation of azospermia) prior to the female subject's entry into the study and is the sole sexual partner for that female subject,
  • Double barrier method-condom or occlusive cap (diaphragm or cervical /vault caps) plus spermicide,
  • Estrogenic vaginal ring
  • Diagnosis of PAR to include:
  • A positive skin test (by prick method) response to appropriate perennial allergen (house dust mites, animal dander, mold, or cockroach) within last 12 months prior to Visit 1 or at Visit 1.

A positive skin test is defined as a wheal ≥3mm larger than the diluent control for prick testing.

  • Two year medical history and past treatment of PAR (written or verbal confirmation) which includes perennial, i.e., year-round, symptoms. PAR symptoms would include nasal congestion, rhinorrhea, nasal itching and sneezing, eye itching/burning, eye tearing/watering, and eye redness.

In vitro tests for specific IgE (such as RAST, PRIST) will not be allowed for the diagnosis of PAR.

NOTE: Subjects who meet the above criteria for PAR and who also have a history of allergy to a seasonal pollen that will be present in their geographic area during study participation are NOT eligible for randomization.

  • Environment
  • Subject must be symptomatic to appropriate perennial allergen (animal dander, house dust mites, cockroach, mold) and willing to maintain same environment throughout the study.
  • Ability to comply with study procedures
  • Subject understands and is willing, able and likely to comply with study procedures and restrictions.
  • Literate
  • Subject must be able to read, comprehend, and record information in English or native language.

Randomization Criteria

At Visit 2, the subject must meet the following criteria:

  • Average of the last 8 rTNSS assessments (4 AM assessments, 4 PM assessments) over the four 24-hours periods prior to randomization must be ≥6. This includes the AM assessment on the morning of the randomization visit.
  • Average of the last 8 reflective nasal symptom assessments for congestion (4 AM assessments, 4 PM assessments) over the four 24-hour periods prior to randomization must be ≥2. This includes the AM assessment on the morning of the randomization visit.
  • Average of the last eight rTOSS assessments (4 AM assessments, 4 PM assessments) over the four 24-hour periods prior to randomization must be ≥ 4. This includes the AM assessment on the morning of the randomization visit.
  • The subject has demonstrated the ability to comply with the use of the daily e-diary, defined as completion of at least 80% of the assessments during the screening period.

Exclusion Criteria:

Subjects meeting any of the following criteria must not be enrolled in the study:

  • Significant concomitant medical conditions, defined as but not limited to:
  • a historical or current evidence of clinically significant uncontrolled disease of any body system (e.g., tuberculosis, psychological disorders, eczema). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or which would confound the interpretation of the study results if the disease/condition exacerbated during the study.
  • a severe physical obstruction of the nose (e.g., deviated septum or nasal polyp) or nasal septal perforation that could affect the deposition of double blind intranasal study drug
  • nasal (e.g., nasal septum) or ocular injury/surgery in the last 3 months
  • asthma, with the exception of mild intermittent asthma [NAEPP, 2007; GINA, 2006], or very mild asthma (Canada) [Lemiére, 2004].

NOTE: Subjects will be allowed to use short-acting inhaled beta2 agonists ONLY on an as needed basis.

  • rhinitis medicamentosa
  • bacterial or viral infection (e.g., common cold) of the eyes or upper respiratory tract within two weeks of Visit 1 or during the screening period
  • documented evidence of acute or significant chronic sinusitis, as determined by the individual investigator
  • current or history of glaucoma and/or ocular herpes simplex
  • current cataract
  • physical impairment that would affect subject's ability to participate safely and fully in the study
  • clinical evidence of a Candida infection of the nose
  • history of psychiatric disease, intellectual deficiency, poor motivation, substance abuse (including drug and alcohol) or other conditions that will limit the validity of informed consent or that would confound the interpretation of the study results
  • history of adrenal insufficiency
  • Use of corticosteroids, defined as:
  • Intranasal corticosteroid within 4 weeks prior to Visit 1 (e.g., FLONASE™, VERAMYST, Nasonex, Rhinocort).
  • Inhaled, oral, intramuscular, intravenous, ocular, and/or dermatological corticosteroid (with the exception of hydrocortisone cream/ointment, 1% or less, or equivalent) within 8 weeks prior to Visit 1.
  • Use of other allergy medications within the timeframe indicated relative to Visit 1
  • Intranasal or ocular cromolyn within 14 days prior to Visit 1 (e.g., Nasalcrom, Crolom)
  • Short-acting prescription and non-prescription antihistamines, including ocular preparations and antihistamines contained in insomnia and "night time" pain formulations, within 3 days prior to Visit 1 (e.g., Benadryl, Chlortrimeton, Dimetane, Tavist)
  • Long-acting antihistamines within 10 days prior to Visit 1, including loratadine, desloratadine, fexofenadine, cetirizine, levocetirizine, terfenadine (e.g., Allegra, Claritin, Clarinex, Zyrtec)
  • Long-acting antihistamine, astemizole, within 12 weeks prior to Visit 1
  • Intranasal antihistamines (e.g., Astelin) within 2 weeks prior to Visit 1
  • Oral or intranasal decongestants within 3 days prior to Visit 1 (e.g., Sudafed)
  • Long-acting beta-agonists within 3 days prior to Visit 1 (e.g., SEREVENT™, Foradil)
  • Intranasal, oral, or inhaled anticholinergics within 3 days prior to Visit 1 (e.g., Atrovent)
  • Histamine H2-receptor antagonists including cimetidine, ranitidine, famotidine, nizatidine (e.g., ZANTAC™, Tagamet, Pepcid, Axid) within 1 day prior to Visit 1
  • Oral antileukotrienes within 3 days of Visit 1 (e.g., Singulair)
  • Subcutaneous omalizumab (Xolair) within 5 months of Visit 1
  • Subjects are not permitted to use any artificial tears, eyewashes/nasal irrigation solutions, homeopathic preparations, lubricants, sympathomimetic or vasoconstrictor preparations during the screening and treatment periods. No exclusion period prior to screening (Visit 1) is required for these treatments.
  • Use of other medications that may affect allergic rhinitis or its symptoms
  • Chronic use of concomitant medications, such as tricyclic antidepressants, that would affect assessment of the effectiveness of the study drug
  • Use of other intranasally administered medications (e.g., Miacalcin)
  • Use of immunosuppressive medications eight weeks prior to screening and during the study
  • Immunotherapy Immunotherapy patients may be enrolled in the study as long as the immunotherapy was not initiated within 30 days of Visit 1 and if the dose has remained fixed over the 30 days prior to Visit 1, and the dose will remain fixed for the duration of the study.
  • Use of any medications that significantly alter the pharmacokinetics of fluticasone furoate, including ritonavir and ketoconazole
  • Allergy/Intolerance
  • Known hypersensitivity to corticosteroids, or any excipients in the product
  • Use of contact lenses
  • Use of Nasal Continuous Positive Airway Pressure (C-PAP) device (mask or pillow)
  • Clinical trial/experimental medication experience
  • Participation in a clinical trial within 12 months prior to Visit 1
  • Participation in a previous or current FFNS (GW685698X) clinical study
  • Positive pregnancy test or female who is breastfeeding
  • Has a positive or inconclusive pregnancy test at Visit 1 or Visit 2
  • Affiliation with investigational site
  • Subject is a participating investigator, sub-investigator, study co-ordinator, or employee of a participating investigator, or is an immediate family member of the aforementioned.
  • Current tobacco use
  • Subject currently uses, or has used within the past year, smoking products including cigarettes, cigars, and pipe or chewing tobacco.
  • Chickenpox or measles
  • A subject is not eligible if he/she currently has chickenpox or measles, or has been exposed to chickenpox or measles during the last three weeks and is non-immune. If a subject develops chickenpox or measles during the study, he/she will be withdrawn from the study. If a non-immune subject is exposed to chickenpox or measles during the study, his/her continuation in the study will be at the discretion of the investigator, taking into consideration the likelihood of developing active disease.
  • Findings of a clinically significant, abnormal electrocardiogram (ECG)
  • Findings of a clinically significant laboratory abnormality
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00609674

  Hide Study Locations
Locations
United States, Maryland
GSK Investigational Site
Baltimore, Maryland, United States, 21236
GSK Investigational Site
Wheaton, Maryland, United States, 20902
United States, Massachusetts
GSK Investigational Site
North Dartmouth, Massachusetts, United States, 02747
United States, Minnesota
GSK Investigational Site
Minneapolis, Minnesota, United States, 55402
GSK Investigational Site
Plymouth, Minnesota, United States, 55441
United States, Missouri
GSK Investigational Site
St. Louis, Missouri, United States, 63141
United States, Nebraska
GSK Investigational Site
Lincoln, Nebraska, United States, 68505
United States, New Jersey
GSK Investigational Site
Ocean, New Jersey, United States, 07712
United States, Ohio
GSK Investigational Site
Canton, Ohio, United States, 44718
United States, Rhode Island
GSK Investigational Site
Providence, Rhode Island, United States, 02906
United States, Vermont
GSK Investigational Site
South Burlington, Vermont, United States, 05403
United States, Wisconsin
GSK Investigational Site
Greenfield, Wisconsin, United States, 53228
Canada, Manitoba
GSK Investigational Site
Winnipeg, Manitoba, Canada, R2M 5L9
Canada, Newfoundland and Labrador
GSK Investigational Site
Saint John's, Newfoundland and Labrador, Canada, A1A 3R5
Canada, Ontario
GSK Investigational Site
Hamilton, Ontario, Canada, L8N 3Z5
GSK Investigational Site
Kanata, Ontario, Canada, K2L 3C8
GSK Investigational Site
Mississauga, Ontario, Canada, L5A 3V4
GSK Investigational Site
Ottawa, Ontario, Canada, K1Y 4G2
GSK Investigational Site
Toronto, Ontario, Canada, M9W 4L6
Canada, Quebec
GSK Investigational Site
Quebec City, Quebec, Canada, G1V 4M6
GSK Investigational Site
Trois Rivières, Quebec, Canada, G8T 7A1
Canada, Saskatchewan
GSK Investigational Site
Saskatoon, Saskatchewan, Canada, S7H 0V1
Estonia
GSK Investigational Site
Tallinn, Estonia, 13419
GSK Investigational Site
Tartu, Estonia, 51014
Germany
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30159
GSK Investigational Site
Magdeburg, Sachsen-Anhalt, Germany, 39112
GSK Investigational Site
Berlin, Germany, 10787
Hungary
GSK Investigational Site
Budapest, Hungary, 1116
GSK Investigational Site
Budapest, Hungary, 1148
GSK Investigational Site
Budapest, Hungary, 1204
GSK Investigational Site
Budapest, Hungary, 1015
Russian Federation
GSK Investigational Site
Moscow, Russian Federation, 123095
GSK Investigational Site
Moscow, Russian Federation, 115478
GSK Investigational Site
Saint-Petersburg, Russian Federation, 190013
Slovakia
GSK Investigational Site
Banska Bystrica, Slovakia, 975 17
GSK Investigational Site
Bratislava, Slovakia, 812 50
GSK Investigational Site
Presov, Slovakia, 080 01
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Study Director, GSK
ClinicalTrials.gov Identifier: NCT00609674     History of Changes
Other Study ID Numbers: FFU111439
Study First Received: January 24, 2008
Results First Received: June 22, 2009
Last Updated: January 5, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
Perennial allergic rhinitis; fluticasone furoate nasal spray

Additional relevant MeSH terms:
Rhinitis
Rhinitis, Allergic, Perennial
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Fluticasone
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Dermatologic Agents
Anti-Allergic Agents
Anti-Inflammatory Agents

ClinicalTrials.gov processed this record on April 21, 2014